
Fidaxomicin
CAS No. 873857-62-6
Fidaxomicin( OPT-80 | PAR-101 )
Catalog No. M16356 CAS No. 873857-62-6
Fidaxomicin(OPT-80; PAR-101) is a?new class of narrow spectrum macrocyclic antibiotic drug.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 32 | In Stock |
![]() ![]() |
10MG | 36 | In Stock |
![]() ![]() |
25MG | 49 | In Stock |
![]() ![]() |
50MG | 67 | In Stock |
![]() ![]() |
100MG | 113 | In Stock |
![]() ![]() |
200MG | 167 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameFidaxomicin
-
NoteResearch use only, not for human use.
-
Brief DescriptionFidaxomicin(OPT-80; PAR-101) is a?new class of narrow spectrum macrocyclic antibiotic drug.
-
DescriptionFidaxomicin(OPT-80; PAR-101) is a?new class of narrow spectrum macrocyclic antibiotic drug, selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria.Bacterial Infection Approved(In Vitro):Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.Fidaxomicin is not inhibitory to commonly cultured bowel commensals (MIC90 >1024?μg/mL).(In Vivo):Fidaxomicin (0-5 mg/kg, Orally, once a day for 5 days) completely prevents the lethality of the animals and prevents the occurrence of relapses in a hamster model for pseudomembranous colitis.
-
In VitroFidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.Fidaxomicin is not inhibitory to commonly cultured bowel commensals (MIC90 >1024?μg/mL).
-
In VivoFidaxomicin (0-5 mg/kg, Orally, once a day for 5 days) completely prevents the lethality of the animals and prevents the occurrence of relapses in a hamster model for pseudomembranous colitis. Animal Model:Male Golden Syrian hamsters (80-100 g, Hamster model for pseudomembranous colitis)Dosage:0.2, 1, and 5 mg/kg Administration:Orally, once a day for 5 days, beginning 8 h after infectionResult:Completely prevented the lethality of the animals. Completely prevented the development of antibiotic-induced C. difficile colitis in hamsters at doses as low as 0.2 mg/kg.
-
SynonymsOPT-80 | PAR-101
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorRNApolymerase
-
Research AreaInfection
-
IndicationBacterial Infection
Chemical Information
-
CAS Number873857-62-6
-
Formula Weight1058.039
-
Molecular FormulaC52H74Cl2O18
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESO=C(O[C@@H]1[C@@H](C)O[C@@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@H]3[C@@H](O)[C@@H](O)[C@H](OC(C(C)C)=O)C(C)(C)O3)/C(C)=C/C(C)=C/C[C@@H]([C@H](O)C)OC2=O)[C@@H](OC)[C@H]1O)C4=C(O)C(Cl)=C(O)C(Cl)=C4CC
-
Chemical NameOxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
CB-618 sodium salt
CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates.
-
VU 0038882
A small molecule activator of S. aureus HssRS (heme sensor system) that induces endogenous heme biosynthesis by perturbing central metabolism.
-
Phanquinone
Phanquinone is active against a wide range of Gram-positive and Gram-negative organisms.?